Autus Valve Pivotal Study

Last updated: January 6, 2025
Sponsor: Autus Valve Technologies, Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Congenital Heart Disease

Pentalogy Of Cantrell

Heart Disease

Treatment

Pulmonary Valve Replacement Surgery

Clinical Study ID

NCT05006404
AUT-CP-001
  • Ages 18-16
  • All Genders

Study Summary

Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.

The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study.

  1. Age 18 months to 16 years.

  2. Male or female.

  3. Subject has a native or repaired right ventricular outflow tract.

  4. Subject has been recommended for surgical pulmonary valve replacement by treatingclinical team (cardiologist and cardiac surgeon).

  5. Subject has at least one of the following echocardiographic findings:

  6. Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60mmHg);

  7. Moderate or greater pulmonary regurgitation;

  8. Moderate or greater pulmonary stenosis plus moderate or greater pulmonaryregurgitation.

  9. Subject's body size is suitable for implantation of a study device ranging from 12.7to 22 mm (internal diameter).

  10. Subject and parent/legal representative, where appropriate, are willing to provideinformed written consent.

  11. Subject and parent/legal representative, where appropriate, and treating physicianagree that the subject will return for, and comply with, all required studyassessments and follow-up visits.

Exclusion

Exclusion Criteria:

Candidates will be excluded from the study if any of the following conditions are met:

  1. Subject requires valve replacement in a non-pulmonary position.

  2. Subject has a prosthetic valve at other valve position or will need a prostheticvalve at other valve position (i.e., anticipate additional valve replacements neededwithin 3 years).

  3. Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg).

  4. Subject has pulmonary atresia and major aortopulmonary collaterals.

  5. Subject has significant peripheral pulmonary artery stenosis.

  6. Subject has an active infection requiring current systemic antibiotic therapy (iftemporary illness, subject may be a candidate 4 weeks after discontinuation ofantibiotics).

  7. Subject has active endocarditis or a history of infective endocarditis.

  8. Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renaldisease.

  9. Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)

  10. Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6mmol/L).

  11. Subject has thrombocytopenia (defined as platelet count <50 x 103/µL.

  12. Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs.

  13. Subject has a known autoimmune disease or receives immunosuppressant and/orimmunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC)believes may negatively affect study outcomes.

  14. Subject needs emergency cardiac or vascular surgery or intervention.

  15. Positive pregnancy test prior to valve implant procedure in female subjects who havehad their first menses.

  16. Subject has, in the opinion of the Investigator, a life expectancy of less than 5years.

  17. Subject or parent/legal representative refuses blood transfusions.

  18. Subject has medical, social or psychosocial factors that, in the opinion of theInvestigator or ESC, could impact safety or compliance with study procedures.

  19. Subject is participating in an investigational study of a new drug, biologic ordevice at the time of study screening.

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Pulmonary Valve Replacement Surgery
Phase:
Study Start date:
February 05, 2024
Estimated Completion Date:
February 29, 2036

Connect with a study center

  • Children's Hospital Los Angeles

    Los Angeles, California 90027
    United States

    Active - Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado 80045
    United States

    Active - Recruiting

  • Children's Healthcare of Atlanta

    Atlanta, Georgia 30322
    United States

    Active - Recruiting

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois 60611
    United States

    Active - Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts 02115
    United States

    Active - Recruiting

  • University of Michigan - Mott Children's Hospital

    Ann Arbor, Michigan 48109
    United States

    Active - Recruiting

  • Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital

    New York, New York 10032
    United States

    Active - Recruiting

  • Duke University

    Durham, North Carolina 27703
    United States

    Active - Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio 43205
    United States

    Active - Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

  • University of Utah - Intermountain Primary Children's Hospital

    Salt Lake City, Utah 84113
    United States

    Active - Recruiting

  • Seattle Children's Hospital

    Seattle, Washington 98105
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.